Cargando…

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia

INTRODUCTION: Benign prostatic hyperplasia (BPH) is a common condition affecting older men. Bothersome symptoms can progress to serious complications such as acute urinary retention (AUR) requiring surgical intervention. Dutasteride, a dual 5-alfa-reductase (5AR) inhibitor (5ARI), is a recently intr...

Descripción completa

Detalles Bibliográficos
Autor principal:	Thomson, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2005
Materias:	Clinical Impact Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321661/ https://www.ncbi.nlm.nih.gov/pubmed/22500150

Ejemplares similares

Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride
por: Khedmati, Jamaleddin, et al.
Publicado: (2021)

Etanercept in psoriasis: the evidence of its therapeutic impact
por: Thomson, Andrew
Publicado: (2007)

Perindopril: the evidence of its therapeutic impact in hypertension
por: Thomson, Andrew, et al.
Publicado: (2007)

Fosphenytoin for the treatment of status epilepticus: an evidence-based assessment of its clinical and economic outcomes
por: Thomson, Andrew
Publicado: (2005)

A Dual 5α-Reductase Inhibitor Dutasteride Caused Reductions in Vascular Density and Area in Benign Prostatic Hyperplasia
por: Zaitsu, Masayoshi, et al.
Publicado: (2013)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis
por: Profit, Louise, et al.
Publicado: (2007)

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis
por: Li, Yao, et al.
Publicado: (2022)

Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride
por: Kuiper, Josephina G., et al.
Publicado: (2016)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
por: Knowles, Joanne
Publicado: (2006)

The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model
por: Da Silva, Marcello H A, et al.
Publicado: (2018)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
por: Miller, Joe, et al.
Publicado: (2007)

Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
por: Toren, Paul, et al.
Publicado: (2013)

Changes in Sexual Function in Benign Prostatic Hyperplasia Patients Taking Dutasteride: 1-Year Follow-Up Results
por: Chi, Byung Hoon, et al.
Publicado: (2011)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Ivabradine: the evidence of its therapeutic impact in angina
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2008)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Efficacy and safety of dutasteride with tadalafil add-on therapy in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia
por: Gotoh, Daisuke, et al.
Publicado: (2022)

Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: nationwide cohort study
por: Laanani, Moussa, et al.
Publicado: (2023)

A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model
por: Udeh, Emeka I., et al.
Publicado: (2016)

Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials
por: Zhou, Zhongbao, et al.
Publicado: (2020)

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects
por: Zamuner, Marina, et al.
Publicado: (2014)

Preparation, Characterization and Stability Study of Dutasteride Loaded Nanoemulsion for Treatment of Benign Prostatic Hypertrophy
por: Ali, Mohammad Sajid, et al.
Publicado: (2014)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

An evidence-based review of NX1207 and its potential in the treatment of benign prostatic hyperplasia
por: Kunit, Thomas, et al.
Publicado: (2014)

Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value
por: Clissold, Rhian, et al.
Publicado: (2007)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia
por: Yu, Haining, et al.
Publicado: (2015)

Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk
por: Hung, S-C, et al.
Publicado: (2013)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Characteristics of prostate biopsy in patients under the dutasteride treatment
por: Obinata, Daisuke, et al.
Publicado: (2022)

Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database
por: Lulic, Zrinka, et al.
Publicado: (2021)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n4v54le5ng5k5omhbtnhduq2g1